A combination of low TMB and PD-L1 expression predict poor progression-free survival of metastatic melanoma patients treated with first-line ipilimumab plus nivolumab

Key Points

• Low tumor mutation burden and expression of pd-l1 are linked to poor progression-free survival in metastatic melanoma patients.
• Patients with low tmb and high pd-l1 levels have limited responses to first-line ipilimumab plus nivolumab treatment.
• Assessment of predictive biomarkers highlights the potential of developing a nomogram for better treatment outcomes.
• Further research is needed to validate these findings and enhance predictive accuracy for immunotherapy benefits.

Abstract